Navigation Links
Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process

THOUSAND OAKS, Calif., March 11 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the methods of expressing, secreting, and purifying the NELL-1 sequence of the UCB-1 recombinant protein wherein the mammalian cell line comprises a Chinese hamster ovary (CHO) cell. This patent continues the creation of a patent portfolio for musculoskeletal applications of manufacturing and use in bone regeneration and repair as well as cartilage regeneration and repair.  

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort. This platform technology is combined with DBX® demineralized bone matrix, to promote bone growth in spinal fusion. DBX® is a product of the Musculoskeletal Transplant Foundation, a Bone Biologics partner.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.    

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "This patent issuance is a significant milestone in our efforts to realize the full potential of the UCB-1 protein as a platform technology. We very much appreciate the continued support of MTF on this project."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clive Dix Appointed as Chairman of Crescendo Biologics
2. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
3. PhRMA Statement Supporting Fair Incentives for Biologics Innovation
4. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
5. CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License
6. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
7. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
8. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
11. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
Post Your Comments:
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
(Date:11/27/2015)... Nov. 26, 2015 ... of the "2016 Global Tumor Marker ... Volume and Sales Segment Forecasts, Innovative Technologies, ... report to their offering. --> ... the "2016 Global Tumor Marker Testing ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... , ... November 26, 2015 , ... PRMA Plastic Surgery ... 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! , “What ... up every day excited to rebuild lives and it’s an honor to have served ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ... These classically-influenced trailer titles work with any font, giving users limitless opportunities to ...
Breaking Medicine News(10 mins):